Infex is a clinical-stage R&D infectious disease specialist, that acquires, develops, and licenses innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring a new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Our mission is to ensure that all new, novel and needed drugs can get to market in the shortest possible time.
We have developed a partnering model to support this aim. It will progress research through to clinical trial quickly so that treatments can be brought to market and the threat from infectious diseases can be significantly reduced.
